MedTrace Logo

The Safety and Tolerability of CLZ-2002 in Patients With Charcot-Marie Tooth Disease.

NCT05947578 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-02-17

No results posted yet for this study

Summary

A Phase 1, Open-Label, Prospective, Dose-finding Clinical Trial for Evaluation of Safety and Tolerability of Intramuscular Injections of CLZ-2002 for the Treatment of Subjects with Charcot-Marie-Tooth type 1(CMT 1)

Conditions

  • Charcot Marie Tooth Disease, Type 1

Interventions

DRUG

CLZ-2002

Low dose group (6×10\^6 cells), Mid dose group (12×10\^6 cells), High dose group (24×10\^6 cells)

Sponsors & Collaborators

  • Cellatoz Therapeutics, Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-19
Primary Completion
2024-08-09
Completion
2024-08-09

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05947578 on ClinicalTrials.gov